ライフサイエンスコーパス: kidney function

1 istics, comorbidities, albumin, and residual kidney function).

2 erved in other ciliopathies with compromised kidney function).

3 y and effectiveness in patients with reduced kidney function.

4 e proximal tubules is an essential intrinsic kidney function.

5 -1.7% (95% CI: 0.5% to -2.8%) with preserved kidney function.

6 mes with evolocumab and placebo according to kidney function.

7 e kidney injury (AKI) and subsequent loss of kidney function.

8 ing treatments can slow the deterioration of kidney function.

9 with transplantation outcomes and subsequent kidney function.

10 t stress which contributes to the decline in kidney function.

11 ed with cardiovascular disease, diabetes and kidney function.

12 3 deficiency models rescued msuPAR2-mediated kidney function.

13 ateral renal cysts that lead to a decline in kidney function.

14 e-lowering medication after reaching reduced kidney function.

15 FB mAbs also extended survival and preserved kidney function.

16 postoperative AKI and for subsequent loss of kidney function.

17 1.10-2.47, p=0.015), independent of baseline kidney function.

18 reases in severity with the deterioration of kidney function.

19 erally caused due to the progressive loss of kidney function.

20 genous creatinine was used to evaluate early kidney function.

21 e beneficial effect of CoQ for maintenace of kidney function.

22 s a critical regulator of podocyte and hence kidney function.

23 stages, leading to severe postnatal loss of kidney function.

24 ease acid excretion but lead to a decline in kidney function.

25 reduction of albuminuria and preservation of kidney function.

26 nephropathy, whereas CB1R blockade improves kidney function.

27 non-coding genomic regions, associated with kidney function.

28 lating GDF-15 are associated with decline in kidney function.

29 ect kidney's filtration barrier and preserve kidney function.

30 lead to progressive fibrosis and decline in kidney function.

31 herapy-related changes in serum potassium or kidney function.

32 s and inflammation and associated with worse kidney function.

33 into complex structures that replicate human kidney function.

34 cipants to identify epigenetic signatures of kidney function.

35 on, gene expression patterns, DSA levels, or kidney function.

36 site in the terminal exon) is protective for kidney function.

37 ix accumulation, organ scarring, and loss of kidney function.

38 ation of nephrons in situ to restore failing kidney function.

39 poor renal outcomes in patients with normal kidney function.

40 y associated with a lower risk of decline in kidney function.

41 k of renal scarring and irreversible loss of kidney function.

42 SCs did not decrease the time to recovery of kidney function.

43 ovascular disease among patients with normal kidney function.

44 rtality and recipients who may regain native kidney function.

45 ovascular disease in populations with normal kidney function.

46 kedly attenuated cyst formation and restored kidney function.

47 re accurate predictors of recovery of native kidney function.

48 between soluble klotho levels and change in kidney function.

49 of annual deaths in individuals with normal kidney function.

50 se oligonucleotides and improved post-injury kidney function.

51 nor allele frequency >5% are associated with kidney function.

52 dysfunction, myocyte injury and stress, and kidney function.

53 etabolites among 1,627 patients with reduced kidney function.

54 r and kidney outcomes across the spectrum of kidney function.

55 ed for dialysis, or persistent impairment in kidney function.

56 s and T cells, precluding any improvement of kidney function.

57 t Study to identify epigenetic signatures of kidney function.

58 antihypertensive medications, and had lower kidney function.

59 on, but at the short-term expense of reduced kidney function.

60 ure and provided extraordinary insights into kidney function.

61 red erythropoiesis in the setting of reduced kidney function.

62 require RRT and were less likely to recover kidney function.

63 tasis is maintained in patients with healthy kidney function.

64 gesting that SHROOM3 will be responsible for kidney function.

65 act of asymptomatic replication on long-term kidney function.

66 yperglycemia) were not associated with worse kidney function.

67 evealed AMR in 63 cases (73%), regardless of kidney function.

68 treatment strategies in people with reduced kidney function.

69 arding risk of NSF in patients with impaired kidney function.

70 ing a substantial number of PWH with reduced kidney function.

71 effectiveness and safety across the range of kidney function.

72 ting that albuminuria leads to impairment of kidney function.

73 in plasma and iWAT, and evaluated liver and kidney functions.

74 del disease and to restore or replace normal kidney functions.

75 rters, and angiocrine factors choreographing kidney functions.

76 pH maintenance, as well as other specialised kidney functions.

77 ates kidney damage and fibrosis and improves kidney functions.

78 (16.8%), hyperkalemia (13.2%), and worsening kidney function (12.3%).

79 There were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with

80 The 5 most commonly reported domains were kidney function (154, 58%), time to discharge (96, 36%),

81 atients using NOACs declined with decreasing kidney function-73.5%, 69.6%, 65.4%, 59.5%, and 45.0% of

82 2-weeks post-doxorubicin completely restored kidney function accompanied with an increase Treg and IL

83 13, canagliflozin slowed the annual loss of kidney function across albuminuria subgroups, with great

84 Restoration of kidney function after kidney transplant generally improv

85 acking hypertension, proteinuria and reduced kidney function after workup will not possess APOL1 high

86 ference in adjusted associations by level of kidney function, age, diabetes status, or body-mass inde

87 2 diabetes is the leading cause of impaired kidney function, albuminuria, and renal replacement ther

88 = 9,192) 30-65 years old and in relation to kidney function among adults > 20 years old (n = 29,499)

89 identify a novel pathway involved in loss of kidney function among patients with CKD.

90 uncovered novel epigenetic associations with kidney function among people living with HIV and suggest

91 Among the factors influencing kidney function, an angio-CT during the same hospital st

92 A 41-year-old man presented with declining kidney function and a serum creatinine of 2.7 mg/dL.

93 In obesity, abnormal kidney function and associated increases in tubular sodi

94 atients aged 18 years or younger with stable kidney function and available serum creatinine (SCr) mea

95 NK could be associated with deterioration of kidney function and could have a role as a novel renal m

96 Impaired kidney function and earlier menopause were associated wi

97 mones, FGF23 and osteocalcin, which regulate kidney function and glucose homeostasis, respectively.

98 nced stages of kidney disease independent of kidney function and glycemia.

99 s in animals with Alport Syndrome, enhancing kidney function and improving survival.

100 type was strongly associated with decreasing kidney function and increasing 24-hour proteinuria in ch

101 Kidney function and injury were assessed using the avera

102 We assessed kidney function and injury with standard techniques and

103 , Sirt5(-/-) mice had significantly improved kidney function and less tissue damage compared with con

104 CKD such as renal hypoxia result in loss of kidney function and limit engraftment and therapeutic ef

105 Endothelial deletion of Phd2 preserved kidney function and limited transition to CKD.

106 n vivo inhibition of miR-182 by ASO improved kidney function and morphology after AKI.

107 endent of the natriuretic peptide NT-proBNP, kidney function and of markers of systemic inflammation.

108 been used extensively for the assessment of kidney function and pathology for both research and diag

109 insight into the genetic factors underlying kidney function and progression to CKD.

110 )D clearance from the circulation differs by kidney function and race.

111 dure, the patient maintains normal liver and kidney function and refers significant improvement in qu

112 inical practice guidelines recommend routine kidney function and serum potassium testing within 30 da

113 ow promise for providing unique insight into kidney function and severity of fibrosis.

114 ox dose and serum ferritin concentrations on kidney function and the effect of impaired kidney functi

115 We investigated markers of kidney function and the effect of intensive hypertension

116 GA administration in patients with impaired kidney function and the incidence of nephrogenic systemi

117 Poorer kidney function and the presence of diabetes mellitus, c

118 lomerular filtration rate (eGFR, a marker of kidney function) and serum PFOA concentration were measu

119 ARPKD, especially in patients with residual kidney function, and emphasize the importance of avoidin

120 We analyzed effects on BP, kidney function, and fluid balance and related this to r

121 acteristic of FSGS with proteinuria, loss of kidney function, and glomerulosclerosis.

122 Patients had good bone marrow, liver and kidney function, and good performance status (Eastern Co

123 nformation on the risk factors, particularly kidney function, and impact of long-term cardiovascular

124 es, including glycemic control, albuminuria, kidney function, and kidney function decline.

125 ently associated with more dyspnea, impaired kidney function, and lower cardiac output ( P<0.003 for

126 up (n=14) included subjects matched for age, kidney function, and stenosis severity.

127 eruli) with age, obesity, diabetes, smoking, kidney function, and structural pathology in the superfi

128 Ion channels are critical to kidney function, and their dysregulation leads to severa

129 nction, with incidence of a deterioration of kidney function, and with mortality.

130 ta-cell function, systemic inflammation, and kidney function apparently differed between white and bl

131 Age, CKD risk factors, and kidney function are associated with larger glomerular vo

132 vious studies, earlier menopause and reduced kidney function are the causes rather than the results o

133 on was paid to the influence of preoperative kidney function as well as the impact of the radiologica

134 reatinine clearance remains the mainstay for kidney function assessment, with 74% continuing to use a

135 Our findings highlight kidney function associated epigenetic variation.

136 two large, unrelated cohorts that decline in kidney function associated with APOL1 risk variants was

137 Across 53 tissues, genes in kidney function-associated GWAS loci were enriched in ki

138 his circulating C3 levels, normal liver and kidney function at 26 months of follow-up.

139 need for dialysis, or persistent decline in kidney function at 90 days or for the prevention of cont

140 A higher IPV in combination with a low kidney function at baseline (estimated glomerular filtra

141 Individuals with normal kidney function at baseline with 2 risk alleles had slig

142 8 of 77 (36%) patients who had not recovered kidney function at discharge did so on posthospital foll

143 endently associated with significantly lower kidney function at hospital discharge and after a median

144 oval of the influence of the renal nerves on kidney function attenuates renal neprilysin activity, au

145 atalog, we conducted a GWAS meta-analysis of kidney function based on the estimated glomerular filtra

146 ys, and a clinically significant decrease in kidney function before graft failure.

147 ated with increased risk of deterioration of kidney function between baseline and 9 months (odds rati

148 isk of incident ESRD independent of baseline kidney function but not independent of glycemia.

149 r of glomeruli is a fundamental parameter of kidney function but very difficult to determine using st

150 is an insensitive and non-specific marker of kidney function, but is now used for the very definition

151 Such approaches might slow decline in kidney function, but many patients progress to end-stage

152 t in some patients, TAVR results in improved kidney function by alleviating cardiorenal syndrome.

153 ischarged, 35% had not recovered to baseline kidney function by the time of discharge.

154 with AKI, only 30% survived with recovery of kidney function by the time of discharge.

155 ronary artery calcified plaque (PTPRN2), and kidney function (CDH23, HPCAL1), among others.

156 NEVKP storage significantly improved early kidney function compared with both cold preservation str

157 1 markedly improved the cystic phenotype and kidney function compared with inactivation of Pkd1 alone

158 The new European Kidney Function Consortium (EKFC) equation is a FAS equa

159 glycated albumin), and a latent variable for kidney function (creatinine, cystatin C, beta2-microglob

160 key efficacy outcomes and slowed the rate of kidney function decline in patients with and without CKD

161 or CKD, but the trajectory and predictors of kidney function decline in patients with these phenotype

162 nts with diabetic kidney disease and improve kidney function decline models indicating that they are

163 In total 471 probes improve the model for kidney function decline.

164 dney structural damage and build a model for kidney function decline.

165 c control, albuminuria, kidney function, and kidney function decline.

166 warfarin, NOACs are used less frequently as kidney function declines.

167 ns in earlier stages of CKD and escalates as kidney function declines.

168 primary outcome was the time to recovery of kidney function defined as return of postintervention cr

169 provides a platform for in vitro studies of kidney function, disease modeling, and pharmacology.

170 ith excess cardiovascular disease (CVD), but kidney function does not feature in current CVD risk-pre

171 s, characterized by a progressive decline in kidney function due in part to the formation of fluid-fi

172 HMP resulted in significantly better kidney function during normothermic machine perfusion.

173 In these patients, preservation of kidney function early after LT may lessen the incidence

174 close monitoring and management to preserve kidney function, early planning for vascular access, and

175 0.007) and, in the tertile with both normal kidney function (eGFR 84 +/- 11.7 ml/min/1.73m(2)) and n

176 ents with normal or near-normal preoperative kidney function (eGFR>/=60 ml/min per 1.73 m(2)), partia

177 00 or viruria >=109 copies/mL with estimated kidney function (eGFR) and overall survival for two year

178 exposure to various factors that compromise kidney function, few studies have investigated the assoc

179 ry (AKI) developing in patients with reduced kidney function following exposure to intravenous iodina

180 03 is safe, and that it effectively promotes kidney function following IRI and survival of renal tran

181 estigated as a strategy to improve long-term kidney function following transplanion.

182 out type 2 diabetes and preserved or reduced kidney function from failing.

183 00 or viruria >=109 copies/mL with estimated kidney function (glomerular filtration rate, eGFR) and o

184 trast agent-enhanced examinations and normal kidney function (group 1) or at least one examination an

185 t of adults (>=18 years of age) with reduced kidney function (>=2 measures of estimated glomerular fi

186 The acute loss of kidney function has been diagnosed for many decades usin

187 ctomy versus radical nephrectomy to preserve kidney function has not been well established.

188 People with reduced kidney function have increased cardiovascular disease (C

189 in-function studies of TRPC5 with respect to kidney function have not been reported.

190 splanted CKD patients with similar levels of kidney function impairment and progressive and/or immuno

191 at higher body fatness is one determinant of kidney function impairment with a lowered urine pH even

192 plication of MR-MEGA to trans-ethnic GWAS of kidney function in 71,461 individuals indicates stronger

193 isease [NAFLD]) is associated with decreased kidney function in adults.

194 re, MURs hold great promise for detection of kidney function in both preclinical drug screening and c

195 Discovery of predisposing loci for kidney function in CAD patients was performed using a ge

196 rs139401390 may affect kidney function in CAD patients with mild reduction in e

197 serum creatinine concentration overestimate kidney function in cirrhosis, leading to significant dif

198 l sodium bicarbonate (NaHCO(3)) may preserve kidney function in CKD, even if initiated when serum bic

199 e impact of excessive alcohol consumption on kidney function in critically ill patients.

200 association between plasmin (ogen) uria and kidney function in glomerular diseases remains unclear.

201 the composition of the glycome also affects kidney function in health and disease.

202 Our transcriptome-wide association study of kidney function in healthy kidney tissue identifies 36 p

203 and demonstrate a possible role of impaired kidney function in HF development in asymptomatic person

204 id system might be involved in deteriorating kidney function in HF.

205 e findings, canagliflozin treatment improves kidney function in ISO-treated rats, suggesting that the

206 CrCl and eGFR) provides a better estimate of kidney function in kidney donor candidates than either m

207 /or repair compromises PT length and impairs kidney function in LS patients.

208 n rate (GFR) is central to the assessment of kidney function in medical practice, research and public

209 her suPAR levels are predictive of declining kidney function in patients with ADPKD is unknown.

210 pare oral anticoagulants across the range of kidney function in patients with atrial fibrillation.

211 ude that an eGFR is sufficient for assessing kidney function in patients with cancer undergoing cispl

212 gest that eculizumab treatment may stabilize kidney function in patients with chronic persistent DSA

213 tions, and slowed the progressive decline in kidney function in patients with HF and a reduced ejecti

214 -3 fatty acid supplementation for preserving kidney function in patients with type 2 diabetes.

215 stigate hemolysis, hemopexin deficiency, and kidney function in sickle cell disease (SCD) and report

216 xamine PRS, composed of variants that impact kidney function in the general population, in a posttran

217 To determine whether the acute declines in kidney function in the intensive BP lowering arm of two

218 known which genetic loci are associated with kidney function in the Japanese population, our genome-w

219 of rs139401390 genotypes for risk of reduced kidney function in the overall LURIC study revealed high

220 We characterized baseline kidney function in the REPRIEVE (Randomized Trial to Pre

221 cedural hypoxia, increased RBF, and improved kidney function in this pilot trial.

222 for age, race, traditional CVD risk factors, kidney function, insulin resistance, MRI and dual-energy

223 Normal kidney function involves numerous different cell types,

224 scular disease or chronic kidney disease, if kidney function is adequate.

225 erular filtration rate (eGFR) as a marker of kidney function is commonly used to diagnose CKD.

226 Normal kidney function is exceptional during the early phase of

227 Kidney function is generally well preserved, with transi

228 The best available indicator of overall kidney function is GFR, which is measured either via exo

229 fications of ACTN4 on podocyte integrity and kidney function is not known.

230 multaneous assessment of excretory liver and kidney function is still an unmet need in experimental s

231 id (Sia), and sialylation's crucial role for kidney function is well known.

232 d via the kidneys, an age-related decline in kidney function leads to slower elimination, prolonged a

233 lesterol, atrial fibrillation and changes in kidney function, left ventricular mass or BAD.

234 with hospitalizations across a wide range of kidney function levels.

235 ften accumulate in patients with compromised kidney function, like those with chronic kidney disease

236 er plasma viral RNA, and improved markers of kidney function, liver function, and coagulopathy versus

237 enal pro-inflammatory mediators and salvages kidney function long term.

238 inexpensive treatments can slow the rate of kidney function loss, and because CKD is asymptomatic un

239 ing Global Outcomes criteria, and subsequent kidney function loss, as determined by estimated glomeru

240 n of patients at risk for AKI and subsequent kidney function loss.

241 identifying patients at risk of progressive kidney function loss.

242 e basis of associations with the alternative kidney function marker blood urea nitrogen (n = 416,178)

243 ptophan and pseudouridine as non-traditional kidney function markers.

244 Among hypertensive adults, declining kidney function measured by eGFR is associated with incr

245 consistent across a broad range of baseline kidney function, measured by clinically relevant eGFR su

246 ncluded 1.1 million individuals with reduced kidney function (median follow-up 4.9 years, 45% men, 19

247 e genomic regions that show association with kidney function, methylation, and gene expression.

248 Postoperative decline in kidney function occurred mainly in the first year after

249 tho associated with lower odds of decline in kidney function (odds ratio, 0.78 [95% confidence interv

250 energy generation and, ultimately, the core kidney function of selective solute transport.

251 n kidney function and the effect of impaired kidney function on dose-normalised deferasirox minimum p

252 Of these, 147 were likely to be relevant for kidney function on the basis of associations with the al

253 kidney disease, the impact of pre-operative kidney function on the risk of post-operative pulmonary

254 on produced significant changes in VO2 peak, kidney function, or urine albumin-to-creatinine ratio.

255 tion and associated fibrosis with decline in kidney function over several months.

256 p between pro-ENK level and deterioration of kidney function over time.

257 mmunosuppressive medication (P = 0.001), and kidney function (P = 0.01).

258 T2 inhibitors might attenuate with declining kidney function (p(trend)=0.073), there was clear, separ

259 Among patients with diabetes and reduced kidney function persisting with monotherapy, treatment w

260 y induce systemic damage affecting long-term kidney function posttransplantation.

261 IN28B, can prolong nephrogenesis and enhance kidney function potentially via upregulation of the Igf2

262 ys, and a clinically-significant decrease in kidney function prior to graft failure.

263 hospitalizations accelerated with declining kidney function, reaching as high as 66%.

264 stable ICM and no substantial impairment of kidney function received intracoronary BMC administratio

265 No significant changes in kidney function, rejection rate, or hemoglobin level wer

266 between soluble klotho levels and decline in kidney function (relative decline: eGFR decline >/=30%;

267 n clinical outcomes in patients with reduced kidney function remains unknown.

268 to prevent SLEs and its long-term effects on kidney function should be addressed in future studies.

269 structure, and analysis of their kidneys and kidney function showed vascular destabilization, charact

270 uidelines define this condition as decreased kidney function shown by glomerular filtration rate (GFR

271 scatheter aortic valve replacement (TAVR) on kidney function stage in patients with aortic stenosis r

272 Age, kidney function status, and CVD events were the key dete

273 multiple myeloma and persistent reduction in kidney function strongly affects prognosis.

274 mus (EVR + rTAC) led to significantly better kidney function than standard TAC (TAC-C), without compr

275 merular filtration rate (eGFR), a measure of kidney function that defines CKD, in 312,468 individuals

276 s, risk factors, and the latent variable for kidney function, the linear spline terms representing 1,

277 h nephrotic syndrome and progressive loss of kidney function, thereby encouraging prompt initiation o

278 rmin and sulfonylureas who reached a reduced kidney function threshold (estimated glomerular filtrati

279 Patients were followed up from reduced kidney function threshold until MACE, treatment change,

280 ion reinterprets the genetic architecture of kidney function to identify the gene, tissue, and anatom

281 renal cell carcinoma, is the preservation of kidney function to reduce morbidity and mortality.

282 Integration of GWAS statistics of kidney function traits and gene expression data identifi

283 phenol A (BPA) and phthalates on measures of kidney function, tubular injury, and oxidative stress ov

284 hospitalized pediatric patients with stable kidney function undergoing contrast material-enhanced CT

285 The median time to recovery of kidney function was 15 days with AC607 and 12 days with

286 Kidney function was assessed by measurement of glomerula

287 y, it was associated with acidemia only when kidney function was impaired (creatinine >2 mg/dl), as r

288 Kidney function was significantly better in group 2, if

289 rin inhibitor immunosuppression and preserve kidney function, we have added belatacept to the therape

290 ospitalized, and even moderate reductions in kidney function were associated with elevated rates of h

291 h atrial fibrillation and severely decreased kidney function were excluded from the pivotal non-vitam

292 Patients with reduced kidney function were excluded.

293 arm experienced progressive deterioration of kidney function (which we define as >=4 ml/min/1.73 m2 o

294 se with rapidly progressive deterioration in kidney function, which, histologically, manifests as cre

295 survived for >1840 +/- 1724 days with normal kidney function, while recipients with CAMR (n = 13) sur

296 Conclusion Hospitalized children with stable kidney function who underwent CT with intravenous iodina

297 f delayed >48 h) is associated with improved kidney function with no DGF post-KT, and improved patien

298 as a mediator of the association of baseline kidney function with the 90-day outcome.

299 urse of anemia tends to track the decline in kidney function, with prevalence increasing in more adva

300 creased risk of death rises exponentially as kidney function worsens and is largely attributable to d